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Abstract
RNA interference (RNAi) has become a powerful technique for reverse genetics and drug discovery
and, in both of these areas, large-scale high-throughput RNAi screens are commonly performed. The
statistical techniques used to analyze these screens are frequently borrowed directly from small-
molecule screening; however small-molecule and RNAi data characteristics differ in meaningful
ways. We examine the similarities and differences between RNAi and small-molecule screens,
highlighting particular characteristics of RNAi screen data that must be addressed during analysis.
Additionally, we provide guidance on selection of analysis techniques in the context of a sample
workflow.
Introduction
In recent years, large-scale RNAi libraries that are designed to target complete genomes have
been produced for multiple organisms. When arrayed in 96- or 384-well microplates, with each
well containing reagents that are, in theory, directed against only one gene, genome-scale RNAi
screens are possible using high-throughput screening (HTS) technologies that were developed
for small-molecule screening1. Here, we present a sample workflow for analyzing assay-
endpoint readouts from high throughput RNAi screening data with guidance on choice and
application of relevant statistical methods. Most of the work discussed in this review focuses
on RNAi screens using synthetic small interfering RNA (siRNA), but the methods are also
applicable to RNAi screens performed in microplates with other silencing reagents, including
shRNA (small hairpin RNA), esiRNAs (endoribonuclease-prepared siRNA), and dsRNA
(double stranded RNA).
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Comparing data characteristics of RNAi and small molecule screens
In spite of their dependence on techniques developed for small molecule screens, many groups
have observed anecdotally that there are non-trivial differences between RNAi and small-
molecule HTS data. To more fully characterize such possible differences, we have compared
existing data sets from more than 19 optimized siRNA screens and more than 13 mammalian
cell-based small molecule screens carried out at the ICCB-Longwood Screening Facility at
Harvard Medical School (Supplementary Table 1). Lilliefors tests on the distribution of
measured values across plates containing different siRNA or small molecule reagents showed
that more siRNA screening data were normally distributed. In addition, three simple measures
of assay robustness were investigated: signal-to-background ratio (S/B), coefficient of
variation, and Z′-factor as a measure of the signal window. The median signal to background
ratio, comparing plate mean positive control signal to plate mean negative control, was about
2-fold lower for the siRNA screens compared to the cell-based small molecule screens. The
median coefficient of variation for siRNA assays was twice that of the small molecule assays
(26.5% vs. 13.4%, respectively). Consistent with the decreased S/B ratio and increased
variability of siRNA screens, the Z′-factors from siRNA screens tended to be low (frequently
between 0.0 and 0.5). Thus, overall we find that the siRNA screens are less robust by these
standard measures than small molecule screens. Several plausible reasons for these differences
exist, as outlined below.
Library design
In theory, most siRNA reagents in a genome-scale library should have an expressed cellular
target and knockdown of each target may have physiological effects; RNAi reagents thus have
a higher intrinsic probability for impacting the overall network biology. In contrast, most
compounds in small-molecule screening libraries have no effect on cell pathways because they
lack cellular targets and are de facto negative controls.
Transfection
Even under well-controlled conditions, the transfection process, especially transfection
efficiency, is a major source of variability for siRNA screens. Transfection also causes cell
stress and can affect cell viability, which may have variable and indirect phenotypic effects in
cellular assays.
Kinetics and mechanism of RNAi action
While small molecules rarely affect the actual abundance of the target protein itself, RNAi
reagents reduce—and in some cases nearly eliminate—the target gene product in the cell2.
Because of this mechanistic difference, RNAi reagents generally require 48–72 hours for
maximal effect, whereas small molecules can directly affect their protein targets within hours.
This increased time between cell plating and assay endpoints leads to greater impact of cell
culture and environmental variation on phenotypes and more assay variability in RNAi screens.
In addition, the “window” of maximal RNAi effect likely varies for each gene, but typically a
single endpoint is chosen for a screening assay2. Assaying too early for a given gene produces
a false negative, while assaying too late may lead to false positives due to downstream effects,
thus contributing to weaker, more variable phenotypes in RNAi screens.
Number and quality of controls
RNAi positive controls generally have weaker effects than small molecule positive controls
and, due to variations in transfection efficiencies, may exhibit more inter-well variability than
small molecule controls. Furthermore, while small-molecule screens utilize vehicle-only wells
as negative controls, no such universal negative control exists for siRNA screens since RNAi
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screens usually involve complex delivery vehicles that alone can have biological effects, and
even “non-targeting” siRNA controls may exhibit off-target effects in some cell lines3.
Sequence-specific off-target effects of RNAi4,5,6 due to partial sequence complementarity
between siRNA and messenger RNA complicate interpretation of RNAi experiments. The
mechanisms by which the off-target effects occur are not yet completely understood and thus
they cannot be fully eliminated experimentally.
Since many judgment calls are required in the selection of HTS data analysis strategies, RNAi
researchers should be aware of these differences in order to make appropriate analysis choices,
as discussed below.
RNAi Screening Analysis Workflow
Data analysis takes much longer than most screening groups have anticipated—sometimes
longer than the wet-lab screen itself7,8. Below, we present a sample workflow for analyzing
RNAi HTS data from individual assays with quantitative output. We provide guidance on
choice and application of relevant statistical methods (also summarized in Table 1 and in
Supplementary Table 2). Researchers should keep in mind that, in most situations, there is no
single “correct” analysis method for any data set.
It is worth noting that successful data analysis depends critically on careful experimental design
and assay development prior to the primary screen. Plate layout and placement of control
reagents is important because RNAi screens are particularly susceptible to edge effects or
drifting values across a plate; several suggested layouts have been published9,10,11. It is
advisable to randomize reagent plating location to avoid systematic effects of grouped similar
reagents (although not all labs find this technically feasible). Additionally, siRNA screens of
whole genomes can be carried out in < 30,000 wells and thus can be performed routinely in
duplicate or higher replicate numbers to decrease both false positive and false negative
rates12.
Step 1: Data Triage
To ensure a successful high-throughput screen, data should be examined while the screen is in
progress to allow the identification of potential problems as they occur. Plate visualization is
one of the most effective techniques for uncovering undesirable patterns that might indicate
technical problems (e.g. extreme edge effects or a clogged plate filler manifold). Library plates
that have much higher hit rates than others can also be uncovered by data visualization. Such
an observation would suggest that targeting reagents are non-randomly plated in the library
and that sample-based normalization strategies are inappropriate (Box 1). Visualization
formats developed for small-molecule screens13, including heat maps and plate-well scatter
plots to display overall screen performance, as well as replicate correlation plots to visualize
overall reproducibility (Fig. 1), are equally helpful for RNAi screens. Calculation of various
quality metrics (discussed below) on plates as they are screened can also help ensure the
production of usable data.
Box 1
Normalization strategies: control-based versus sample-based
Some normalization techniques compare individual experimental sample values to
aggregated values of controls, while others use the samples themselves as de facto negative
controls. Some, though not all, techniques can accommodate either approach. The use of
samples as de facto negative controls can provide more accurate measurements because
there are usually more experimental samples than controls on an assay plate. Additionally,
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some assays lack good negative controls that work effectively across all plates. In such
cases, the best available choice is to use the majority of sample wells as a negative reference.
However, this approach is based on the assumption that most samples do not display
biological effect in the assay being analyzed, This assumption needs to be explicitly assessed
by RNAi screeners for their particular assay, especially when using screening libraries
where reagents targeting structurally or functionally related genes are plated together, or
when using a very general assay such as cell viability in which many RNAi reagents may
actually have a biological effect. Clearly, this assumption will also be violated in the case
of confirmatory screens where many primary screening positive reagents are evaluated on
the same assay plate. In these cases, screeners should consider including a large number of
each type of control22 on each assay plate and utilizing control-based statistics instead.
The use of samples as de facto negative controls is especially problematic for non-robust
normalization methods that use statistical measures (such as mean and standard deviation)
that are strongly sensitive to outliers in the data. Such methods may be strongly affected in
RNAi screens containing either large numbers of hits or very strong hits (which will
constitute “outliers” in the sample data).
Step 2: Normalization
Normalization is a process intended to remove systematic errors from the data and to allow
comparison and combination of data from different plates in the screen. Normalization is
generally performed per plate, but is occasionally performed per-experiment when there is a
known confounding per-plate bias such as a large number of true hits on a particular plate
(which may occur when plating of library reagents has been non-random—for example, when
screening a transcription factor siRNA library for genes involved in stem cell differentiation).
Many normalization methods have been developed (see Malo et al 20069 for an overview). An
important issue in this area is the use of on-plate controls vs. samples for normalizing (Box 1).
Most RNAi screeners will find that one of the following methods is suitable to their data and
analysis capacities, and will probably receive acceptable results with any reasonable choice.
As evidence of this, Wiles et al 2008 investigated the effects of seven normalization techniques
(six of which had not previously been applied to RNAi screens) on validation rates of hits
selected for secondary screening from a large-scale Drosophila RNAi screen, but concluded
that no single method excelled.14.
Fraction or percent of control
One common approach, often favored by biologists for its easy calculation and interpretability,
is division of each sample value by the mean of the control of interest (either negative or
positive). This method requires a large number of controls in order to provide adequate
estimation of their mean. Additionally, this method is adequate only for tightly distributed and
“well-behaved” data as it incorporates no information on the variation of the sample
measurements and is sensitive to outliers in the controls.
Fraction or percent of samples
In another common normalization approach, the mean of the samples on the plate may be
substituted for the mean of negative controls in the percent of control calculation, which reduces
the need for large numbers of controls but may exacerbate the issue of non-robustness (Box
1). A more robust variation on this method that is adequate for many screens is division of each
sample value by the median of all samples on the plate, although this method still cannot
incorporate information on the degree of variation in the sample data.
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z-score and robust z-score
z-score (the number of standard deviations from the mean) is frequently used to normalize data
in a way that provides explicit information on the strength of each siRNA relative to the rest
of the sample distribution. An advantage of z-score is its incorporation of information on the
variation in sample measurements, but this method also depends on the use of samples as de
facto negative controls. Because z-score is sensitive to outliers, a variation known as the robust
z-score, which substitutes the outlier-insensitive median and median absolute deviation (MAD)
for mean and standard deviation in the z-score calculation, is generally considered preferable
for RNAi screens.
B score
The above techniques, like most normalization methods, can account for cross-plate systematic
effects but not within-plate systematic effects. If data triage has identified the presence of
within-plate systematic effects, the B score normalization15 may be applied to remove row,
column, or well-level effects by iterative application of the Tukey median polish algorithm. B
score is relatively robust to outliers; however, because its calculation examines the entire plate
to identify systematic effects, it essentially uses the samples as negative controls.
The first three approaches can be easily calculated using standard spreadsheet formulae, while
the B score cannot since it is based on an iterative algorithm. However, a version of the B score
is available in the cellHTS2 package16 of the open-source Bioconductor bioinformatics
software.
Step 3: Calculation of Quality Metrics
Before proceeding to intensive analysis, a screener must ensure that the resulting data meet the
minimum standards of quality to permit legitimate conclusions.
Z′- or Z-Factor
By far the most common quality metrics reported for both RNAi screens and small-molecule
screens are Z- and Z′-factor17. Z′-factor is often used during assay optimization because it is
based on controls, while Z-factor may be used during screening to assess performance of the
screen on actual samples. Note that the Z′- and Z-factor should not be confused with the z-
score discussed above.
where μ indicates mean, σ indicates standard deviation, “ct” indicates the top control, “cb”
indicates the bottom control, “s” indicates sample value, and “c” indicates negative control.
The range of both measures is negative infinity to one, with > 0.5 as a very good assay, > 0 an
acceptable assay, and < 0 an unacceptable assay
A potential issue in using the Z′-factor as a measure of assay resolution is that it is possible to
generate a high Z′-factor using a very strong positive control which may not realistically
represent more moderate screening positives. This issue is of special concern for RNAi screens,
where weak effects might be biologically meaningful and in which the signal-to-background
ratio can be of lower magnitude than in small-molecule screens (Supplementary Table 1). Thus,
researchers are advised whenever possible to use positive controls that are similar in strength
to the hits they anticipate finding. It may also be necessary to adjust Z′-factor quality guidelines
for RNAi screens; the authors of this manuscript have found that assays with Z′-factors of zero
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or greater have been successful in identifying validated hits when library plates were screened
in duplicate or triplicate.
Strictly Standardized Mean Difference (SSMD)
Researchers desiring a more statistically rigorous means to address the limitations of moderate
controls are advised to adopt the Strictly Standardized Mean Difference. SSMD, which was
developed for use with RNAi screening, is the ratio between the difference of the means and
the standard deviation of the difference between two populations (such as positive and negative
controls)18.
Acceptable values for SSMD depend on the strength of the positive controls used, but SSMD
has been shown to be an accurate, less conservative indicator of quality than Z′- or Z-factor,
as demonstrated by examples in which signal-to-noise ratio and Z-factor quality metrics
produce misleading results but SSMD correctly passes the data in question18. Indeed, one of
the authors of this review has incorporated the use of SSMD into quality assessment workflows
and has found it more informative in the context of RNAi screening than the Z′-factor in some
cases. In one case, assaying was performed 20 hours after known maximal response in order
to identify long-term repressors; this extended timeline caused increased variability in high
controls that decreased the Z′-factor below standard acceptable thresholds for the majority of
assay plates. SSMD, on the other hand, accurately captured the clear difference between the
high and low populations.
Receiver Operator Characteristic (ROC) Curves
The Receiver Operating Characteristic curve19 has been used as a quality metric in microarray
transcriptomics20,21, and as it provides a quick and intuitive understanding of dynamic ranges
in data given positive and negative controls, we here highlight it for use in RNAi screening.
ROC curves plot sensitivity versus 1 - specificity (see Supplementary Table 2 for definitions).
The area under the ROC curve can be used as a quality metric, where an area of one represents
a perfect predictor while area of 0.5 represents performance as bad as random chance. One
advantage of ROC curves is that multiple thresholds for defining positives and the resulting
trade-offs between sensitivity and specificity can easily be investigated by plotting multiple
ROC curves. This method has been used to compare validation performance of hits generated
from differently normalized RNAi data14.
Step 4: Hit Identification
The identification of “hits” or “screening positives” is the goal of any primary RNAi screen,
and yet remains a point of considerable contention in data analysis. Hit identification is,
essentially, the process of deciding which sample values differ meaningfully from those of the
negative controls. While some screeners select a discrete number of top scoring samples as
screening positives (often as determined by follow-up capacity), a wide range of hit
identification techniques is available. The selected hit list forms the basis for further validation
screens or investigations.
To reduce the risk of false positives, many practitioners recommend screening multiple
reagents targeting the same gene of interest and selecting hits based on the combined
results6; generally, genes are chosen as hits when a majority of tested reagents are screening
positives, although the Redundant siRNA Activity technique described below offers a more
rigorous approach to combining the results of multiple reagents. False positives may also be
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limited by combining information from multiple screening outputs22, an approach that has
become particularly viable with the advent of high-content screening. While the techniques of
multiparametric analysis are complex and beyond the scope of this work, a useful overview is
available in Ainscow 200723. Such approaches may identify real hits that have high variability
in a single read-out metric22.
Below we discuss the features of both small-molecule derived techniques (mean + or − k
standard deviations, median + or − k MAD and multiple t-tests) and RNAi techniques (quartile-
based selection, SSMD for hit identification, redundant siRNA activity, rank product, and
Bayesian models).
Mean + or − k Standard Deviations
This approach, which involves selecting a standard deviation threshold (k) of the normalized
data relative to the mean and identifying positives as samples that surpass this threshold, is by
far the most frequently used hit identification technique in RNAi screening literature (e.g.,
Bard et al 200624, DasGupta et al 200525). It is often used with z-score normalization, but is
sometimes used on data that has been normalized by other approaches (such as the B score).
This method is particularly appropriate for normally distributed data because the standard
deviations from the mean link to an estimate of the probability that hit values are significantly
different than the distribution of values for de facto negative controls. Another advantage is
that this method is very easy to calculate and implement; however, it is not robust to outliers.
Thus, especially for data in which outliers appear frequently, the application of the commonly
used 3 standard deviation cut-off with this approach tends to miss weak hits, while lowering
the standard deviation threshold to capture such hits may unacceptably increase the rate of false
positives26,27.
Median + or − k MAD
An improvement on the mean + or − k standard deviations approach is median + or − k median
absolute deviation (MAD) (e.g., Muller et al 200528). This method is robust to outliers and has
been shown to identify weak hits in RNAi data more effectively than mean + or k standard
deviations while still capturing the strong hits and controlling false positives27; it has also been
shown to generate fewer false negatives than mean + or − k standard deviations when applied
a non-normal data distribution27, and is also very easy to calculate and implement (although
it sacrifices the former method’s easy link to a probability distribution). For these reasons,
Chung et al 200827 recommend it as the first-choice approach for hit selection in RNAi screens.
Multiple t-tests
For certain assays, such as those comparing RNAi treatment in the presence of drug versus
RNAi treatment alone, it may be appropriate assess the difference in means between replicates
for each condition with multiple t-tests (e.g., Whitehurst et al 200729). This approach is simple
to implement and understand, but it requires three or more replicates of each condition and
assumes normality of the replicate data. In addition, it is imperative to apply multiple-
comparison corrections to the resulting p-values of each individual test if a high false positive
rate cannot be tolerated30, and results of such t-tests are sensitive to outliers31.
Quartile-Based Selection
Researchers who determine that their data distribution is not symmetrical may wish to employ
the quartile-based hit identification method. This approach sets upper and lower hit selection
thresholds based on number of interquartile ranges above or below the first and third quartiles
of the data. Like median + or − k MAD, the quartile method has been shown to identify both
strong hits and weak ones while controlling false positives26. Although this method is easy to
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calculate, it has not been generally implemented in the RNAi screening community, perhaps
because of its modest improvement over the more common median + or − k MAD approach
on approximately normal data. Additionally, in quartile-based selection, as in many other
robust methods, the rankings produced are not easily translatable into p-values.
SSMD for Hit Identification
The Strictly Standardized Mean Difference metric discussed earlier can be employed for hit
identification by screeners concerned with controlling the rate at which siRNAs that have real
large or moderate effects fail to be identified as screening positives as well as the rate at which
siRNAs that should be considered negative are identified as screening positives32. Formulae
are provided33,34 for calculating the SSMD limits for hit selection based on the desired false
positive level, false negative level, or both; while these require a large number of negative
controls (> 50), follow-up work31 provided suggested SSMD cut-offs for screens without large
numbers of negative samples, such as confirmatory screens.
While the SSMD metric has linear relationship to z-score when only one replicate per siRNA
is measured in a screen, these statistically based guidelines may make SSMD more
meaningfully interpretable to researchers. Currently SSMD-based hit identification is not
calculated by standard analysis packages and is not trivial to implement from scratch.
Redundant siRNA Activity (RSA)
The Redundant siRNA Activity (RSA) analysis method35 is appropriate for researchers seeking
to integrate information about multiple RNAi reagents tested for each gene. RSA ranks
silencing reagents according to experimental effect and assigns a p-value to all reagents for a
single gene based on whether the reagents for that gene are distributed significantly higher in
the rankings than would be expected by chance. Because of its use of chance performance as
a basis for statistical calculations, RSA is able to provide p-values for gene hits without
sacrificing robustness.
Positive reagents identified by this method were found to have higher rates of reconfirmation
than those identified with conventional methods, with discrepancies attributable to low
reproducibility of orphan individual siRNAs with high activities35. While RSA is not currently
included in common analysis software packages, its developers have made available
implementations in C# (for Windows), R, and Perl (see
http://carrier.gnf.org/publications/RSA/).
Rank-Product
Screeners intending to perform screens in biological replicate and seeking a robust hit
identification approach that provides estimated p-values may also wish to consider the Rank-
Product method, originally developed for use with microarray data36. The premise of the Rank-
Product approach is that a consistent hit should be highly ranked in each independent biological
replicate set. The rank-product statistic for each sample across all independent sets estimates
this consistency; it can then be translated into a measure of statistical significance by comparing
the observed rank product statistic to a rank product statistic obtained from a large number of
simulated data sets (providing the statistic expected by chance).
This approach provides p-values for potential hits without requiring the assumption of an
underlying probability distribution, but does require significant computation and several
replicates per screen to work. While similar to RSA in its comparison of true data rankings to
those produced by chance, it does not depend on the use of multiple different RNAi reagents
per gene. A Rank-Product implementation suited for use with RNAi screening data has recently
Birmingham et al. Page 8
Nat Methods. Author manuscript; available in PMC 2010 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
been made available as part of the RNAither package37 in the Bioconductor open-source
bioinformatics software.
Bayesian Models
Screeners with appropriate computational resources who seek explicit estimated probabilities
that a given siRNA has no effect, an inhibition effect, or an activation effect (rather than the
single score produced by other methods) may wish to employ a Bayesian approach described
recently by Zhang et al 200838. Bayesian statistics use Bayes’ Theorem to calculate the
probability that a particular hypothesis is true given the observed evidence, and offer a means
to update these probabilities when additional evidence is collected. Zhang et al identify three
hypotheses of interest (an siRNA has no effect, an siRNA has an activation effect, or an siRNA
has an inhibition effect) and develop two models to describe the posterior probability that each
of these hypotheses are true for a particular sample given the evidence of this sample’s observed
value. The first, and simpler, model is based on using only the negative controls to describe
the posterior distribution of the true mean value for the sample given the observed data value.
The second, more complex model describes a posterior distribution that assumes the
availability of data from both positive-inhibition and positive-activation controls as well as
negative controls. Both models also provide the means to calculate the false discovery rate
associated with any given hit threshold, but are usable only on screens done in singlicate.
A strength of this approach is that it incorporates both plate-wide and experiment-wide
information as well as (depending on the model used) information from both negative controls
and the assumed de facto negative samples. When several hit identification approaches were
compared, Zhang et al found the simpler Bayesian model to perform best, followed by plate-
wise median + or − k MAD. Unfortunately, although the published Bayesian models show
great promise, they have not yet been incorporated into commonly available analysis software
and are not trivial to implement. Until software applications implementing Bayesian modeling
are available, the plate-wise median + or −k MAD approach may be the best alternative.
Conclusions and Future Directions
High-throughput RNAi offers a wealth of exciting new data, but also new challenges in the
statistical interpretation of this data. When considering appropriate statistical techniques for
quality control and hit-selection in HTS, it is important to keep in mind that statistical analysis
methods developed in industry for small-molecule screening and therapeutic lead identification
are optimized for a very low false positive rate. RNAi screens, however, appear inherently
more variable and often produce a broader range of biological hits. Thus, researchers applying
small molecule techniques to RNAi data should have a clear understanding of the implicit
assumptions and limitations, and possibly apply altered thresholds to account for common
RNAi-specific data features. Several methods for RNAi HTS data analysis have been
developed specifically with these issues in mind.
The statistical methods outlined here, while certainly not comprehensive, offer effective,
practical tools for RNAi HTS analysis. However, further work is needed; many analysis
techniques continue to favor conservative limits on false positive rates, which artificially
reduce the number of weak and/or variable yet biologically important hits found in screens. In
addition, many researchers are investigating the use of microscopy-based high content assays,
which may eventually offer even more statistical power by providing multiple readouts and
finer characterization of phenotypic results. However, statistical techniques and software for
these assays are still in their infancy; no doubt this area will see significant development effort
in the coming years.
Birmingham et al. Page 9
Nat Methods. Author manuscript; available in PMC 2010 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Finally, it should be emphasized that rigorous secondary screening is necessary to validate
primary screen findings6. Even the best statistics cannot establish the biological significance
of genes identified as primary hits.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Methods for visualizing data outputs of a screen. (a) heat map of raw values from a hypothetical
384-well plate with strong edge effects; (b) replicate correlation plots of raw values from two
hypothetical replicates of the same master plate showing good agreement and suggesting
overall good reproducibility; and (c) plate-well scatter plot of raw values from a hypothetical
screen of eighteen 96-well plates including evidence of drift in the first three plates and a plate
with unusually low values near the end of the screen.
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Table 1
Statistical Analysis Methods for Hit Identification
Strategy Formulae Advantages Disadvantages
Mean + or − k
standard
deviations
Hit with increased activity = any
sample whose value is >= sample
mean + k standard deviations;
Hit with decreased activity = any
sample whose value is <= sample
mean − k standard deviations
Easy to calculate Easily
linked to hit p-values
Sensitive to outliers
Can miss weak positives
Requires multiple comparison corrections if
using p-values
Median + or − k
MAD
Hit with increased activity = any
sample whose value is >= sample
median + k MADs;
Hit with decreased activity = any
sample whose value is <= sample
median − k MADs
Easy to calculate
Can identify weaker hits
Not very sensitive to outliers
Not easily linked to hit p-values
Multiple t-tests Hit = any reagent for which t-test
between samples at two conditions <
threshold (usually p = 0.05 or p =
0.01)
Simple to calculate
Provides hit p-values
Requires triplicates, at minimum
Sensitive to outliers
Inappropriate if data is not normally
distributed
Requires multiple comparison corrections
of p-values
Quartile-based Hit with increased activity = any
sample whose value is > Q3 + c IQR
Hit with decreased activity = any
sample whose value is < Q1 − c IQR
Easy to calculate
Can identify weaker hits
Not sensitive to outliers
Good for non-symmetrical data distributions
Limited additional power over median + or
− k MAD for approximately normal data
Not easily linked to hit p-values
Not available in most analysis software
SSMD Appropriate equations depends on
whether goal is control of rates of
false negatives, false positives or
both
Allows control of both false positive and false
negative rate
Not dependent upon sample size
Linked to rigorous probability interpretation
Not available in most analysis software
Not intuitive for many biologists
RSA Iterative ranking algorithm that
cannot be reduced to a single
equation
Can identify weaker hits
Not sensitive to outliers
Provides hit p-values
May reduce false-positives due to off-target effects
of single reagents
Difficult to calculate
May have limited utility for pool-based
screens
Rank-product Iterative ranking algorithm that
cannot be reduced to a single
equation
Provides hit p-values
Can identify weaker hits
Not sensitive to outliers
Difficult to calculate
Requires many replicates
Bayesian Appropriate equations depend on
whether negative-control or
activation-inhibition-negative
control model is applied
Provides hit p-values
Not sensitive to outliers
Allows direct calculation of false discovery rate
Includes both experiment-wide and plate-wide
information
Uses both negative controls and samples
Difficult to calculate
Not intuitive for many biologists
MAD, median absolute deviation; IQR, interquartile range; SSMD, Strictly Standardized Mean Difference; RSA, Redundant siRNA Activity
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